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Antidepressant stimulation of CDP-diacylglycerol
synthesis does not require monoamine reuptake
inhibition
Marwa A Aboukhatwa2, Ashiwel S Undieh1*
Abstract
Background: Recent studies demonstrate that diverse antidepressant agents increase the cellular production of
the nucleolipid CDP-diacylglycerol and its synthetic derivative, phosphatidylinositol, in depression-relevant brain
regions. Pharmacological blockade of downstream phosphatidylinositide signaling disrupted the behavioral
antidepressant effects in rats. However, the nucleolipid responses were resistant to inhibition by serotonin receptor
antagonists, even though antidepressant-facilitated inositol phosphate accumulation was blocked. Could the
neurochemical effects be additional to the known effects of the drugs on monoamine transmitter transporters? To
examine this question, we tested selected agents in serotonin-depleted brain tissues, in PC12 cells devoid of
serotonin transporters, and on the enzymatic activity of brain CDP-diacylglycerol synthase - the enzyme that
catalyzes the physiological synthesis of CDP-diacylglycerol.
Results: Imipramine, paroxetine, and maprotiline concentration-dependently increased the levels of CDP-
diacylglycerol and phosphatidylinositides in PC12 cells. Rat forebrain tissues depleted of serotonin by pretreatment
with p-chlorophenylalanine showed responses to imipramine or maprotiline that were comparable to respective
responses from saline-injected controls. With fluoxetine, nucleolipid responses in the serotonin-depleted cortex or
hippocampus were significantly reduced, but not abolished. Each drug significantly increased the enzymatic activity
of CDP-diacylglycerol synthase following incubations with cortical or hippocampal brain tissues.
Conclusion: Antidepressants probably induce the activity of CDP-diacylglycerol synthase leading to increased
production of CDP-diacylglycerol and facilitation of downstream phosphatidylinositol synthesis.
Phosphatidylinositol-dependent signaling cascades exert diverse salutary effects in neural cells, including facilitation
of BDNF signaling and neurogenesis. Hence, the present findings should strengthen the notion that modulation of
brain phosphatidylinositide signaling probably contributes to the molecular mechanism of diverse antidepressant
medications.
Background
Neither the pathophysiology of depression nor the
mechanism of action of various antidepressant agents is
fully understood. Accumulating evidence implicates
brain phospholipid metabolism in the actions of diverse
antidepressant drugs [1-3]. For example, diverse antide-
pressant agents increase the cellular production of CDP-
diacylglycerol and its synthetic derivative, phosphatidyli-
nositol, in depression-relevant regions of the rat brain
[2]. Moreover, blockade of downstream inositol phos-
pholipid signaling results in significant disruption of
behavioral antidepressant effects in the rat forced swim
model of depression [3]. These and related observations
have reawakened interest in neural phospholipid systems
as potentially crucial contributors to the pathophysiol-
ogy of depression and/or the mechanism of action of
antidepressant drugs.
CDP-diacylglycerol is a crucial intermediate in the
synthesis of phosphatidylinositol and related signaling
mediators. Enhanced production of CDP-diacylglycerol
can be expected to lead to increased synthesis of phos-
phatidylinositides. Hence, blood platelets incubated with
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different antidepressants show higher levels of phospha-
tidylinositides compared to control platelets, and this
newly synthesized pool of phosphatidylinositides could
be further available for receptor-coupled cell signaling
[4,5]. Another recent study also showed that different
antidepressant drugs induce phosphatidylinositide synth-
esis and facilitate subsequent serotonergic-stimulated
accumulation of inositol phosphate second messengers
[3]. This report also showed that selective blockade of
phosphoinositide-linked 5HT2 serotonin receptors inhib-
ited the effects of antidepressant drugs on inositol phos-
phate accumulation, but the drug effects on CDP-
diacylglycerol production or phosphoinositide synthesis
were not substantially reduced by 5HT2 antagonist
treatment. These observations suggest that the drug
effects on CDP-diacylglycerol and phosphatidylinositide
synthesis involve a mechanism that may not depend on
increased synaptic serotonin action. Clarifying such a
mechanism would increase understanding of depression
pathology, and could lead to the development of new
and better treatment strategies.
The present study was directed at testing the hypoth-
esis that the nucleolipid effects of antidepressants on
CDP-diacylglycerol and its derived inositol phospholi-
pids are substantially independent of the known effects
of the drugs to enhance synaptic serotonin levels. We
evaluated the neurolipid effects of a selection of drugs
in tissues depleted of serotonin, and in neuron-like
PC12 cells that are deficient in receptors and transpor-
ters for serotonin or norepinephrine [6]. Upon observing
that the drugs retained their ability to acutely increase
nucleolipid synthesis, we explored if the drugs might
directly enhance the enzymatic activity of CDP-diacyl-
glycerol synthase, the enzyme that synthesizes CDP-dia-
cylglycerol. The findings suggest that various
antidepressant agents are capable of stimulating the
activity of CDP-diacylglycerol, which might explain the
enhancing effects of the agents on CDP-diacylglycerol
synthesis and phosphatidylinositide production.
Methods
Animals
Male inbred C57BL/6 mice weighing 25-30 g were pur-
chased from Harlan (Indianapolis, Indiana) and housed 5
per cage. Male Sprague-Dawley rats weighing 225-250 g
were purchased from Zivic Laboratories (Pittsburgh, PA)
and housed three per cage. Animals were kept for at least
three days before use and housing was on a 12-hour
light/dark cycle in climate-controlled facilities. Food and
water were freely accessible to each cage of animals. Pro-
tocols for the care and use of the animals were approved
by the Institutional Animal Care and Use Committee and
conformed to the National Institutes of Health Guide for
the Care and Use of Laboratory Animals.
Drugs and chemicals
Buffer reagents and all drugs used were purchased from
Sigma-Aldrich (St. Louis, MO). For the neurolipid
(CDP-diacylglycerol and phosphatidylinositide) assays
and the enzyme activity experiments, test drugs were
dissolved in HEPES bicarbonate (HB) buffer, while for
the cell culture experiments the drugs were dissolved in
phosphate buffered saline. Drugs were prepared fresh
before use.
p-Chlorophenylalanine induction of brain serotonin
depletion
To deplete rat brain tissues of serotonin content, the
animals were administered the tryptophan hydroxylase
inhibitor, p-chlorophenylalanine (PCPA) at the dosage
of 150 mg/kg daily for three days, followed by a 12-h
washout period prior to testing. Control animals
received injections of saline. This regimen of PCPA is
known to result in depletion of 85-95% of forebrain ser-
otonin content without affecting the catecholamines
[7-9].
Measurement of CDP-diacylglycerol synthesis in
serotonin-depleted brain tissues
CDP-diacylglycerol levels in brain tissue preparations
were measured as previously described [2,10]. For the
present study, hippocampal or frontal cortical tissues
were prepared from saline-injected (control) and PCPA-
pretreated rats and processed in parallel. Following a
30-min prelabeling incubation with 0.6 μM 5- [3H]cyti-
dine (20 Ci/mmole, American Radiolabeled Chemicals,
St. Louis, MO), aliquots of slices from each pretreat-
ment group were incubated with various concentrations
of selected antidepressant agents for 90 min, and accu-
mulated [3H]CDP-diacylglycerol measured as previously
described [10].
Measurement of CDP-diacylglycerol and
phosphatidylinositide synthesis in PC12 cells
PC12 cells obtained from ATCC (Manassas, VA) were
maintained in RPMI-1640 Medium supplemented with
5% fetal bovine serum, 10% horse serum and 2 mM L-
glutamine at 37°C with 5% CO2 aeration. The cells were
cultured on poly-D-lysine coated plates until reaching
approximately 80% confluency and then transferred to
Neurobasal medium (Neurobasal+N2 supplement +glu-
tamine) one day before the assay. Cells in wells of a 24-
well plate were labeled with 1.5 μCi [5-3H]cytidine (20
Ci/mmol; ARC, St. Louis, MO) for 30 min to generate a
pool of radiolabeled cytidine triphosphate (CTP). After
addition of 5 mM LiCl, solutions of test drugs were
added to the cells at indicated concentrations and incu-
bation continued for 3 h. To terminate the reaction, 1.5
ml of chloroform-methanol-1 M HCl (100:200:1) was
added with mixing. The lipids were extracted by parti-
tioning to the chloroform layer as described [10,11]; ali-
quots thereof were quantitatively transferred to
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polypropylene tubes and dried overnight at room tem-
perature. Biosafe scintillation cocktail was added to each
sample and the radioactivity determined by liquid scin-
tillation. The radioactivity in each sample corresponds
to [3H]CDP-diacylglycerol as characterized in previous
studies [10,12,13].
For the assay of phosphatidylinositol synthesis, PC12
cells cultured as described above were labeled for one
hour with 1.5 μCi [3H]inositol (20 Ci/mmol; ARC, St.
Louis, MO). Subsequent drug treatments were main-
tained for an incubation period of 3 h, followed by
extraction and quantitation of the inositol phospholipids
as described [10,11].
Measurement of CDP-diacylglycerol synthase activity
CDP-diacylglycerol synthase activity was assayed in
mouse brain membrane preparations according to pre-
viously described methods with minor modifications
[14-16]. Mice were rapidly decapitated and the desired
tissues dissected, chopped into 350-μm slices, and
washed thrice with calcium-free HB buffer. Aliquots of
tissue slices corresponding to approximately 500 μg pro-
tein were distributed into tissue culture wells containing
450 μl HB buffer and incubated at 37°C. Various con-
centrations of each test drug in 50 μl volumes were
added to appropriate tubes and incubation continued
for 3 h. Afterwards, the tissues were transferred into
cold Tris lysis buffer (pH 7.8) containing a cocktail of
protease inhibitors (Sigma-Aldrich, St. Louis, MO) and
lysed by gentle homogenization. Cell debris was
removed by centrifugation (550 × g, 10 min, at 4°C) and
protein concentration of the membrane preparations
was determined by the Bradford method. Equal aliquots
of 25 μg membrane protein were preincubated for 25
min with 3 μM 5- [3H]CTP (specific activity 13.9 Ci/
mmol; Moravek Biochemicals, Brea, CA) in a 50-μl reac-
tion mixture that contained 0.1 M Tris-HCl pH 7.5, 0.2
M KCl, 1 mg/ml bovine serum albumin, 0.1% Triton X-
100, 0.25 mM dithiothreitol, and 200 μM 1,2-dioleoyl-
sn-glycero-3-phosphate. The reaction was started by the
addition of 10 mM MgCl2 and stopped after 20 min by
the addition of chloroform: methanol: 10 M HCl
(1:2:0.02, v/v). After incubating at room temperature for
30 min to extract formed [3H]CDP-diacylglycerol, the
amount of the incorporated radioactivity was deter-
mined by liquid scintillation counting. Assayed enzyme
activity was linear with time up to at least 30 min and
with protein concentration up to at least 50 μg. One
unit of CDP-diacylglycerol synthase activity was defined
as the amount of the enzyme that catalyzed the forma-
tion of one nanomole of CDP-diacylglycerol per minute.
Data analysis
Neurolipid data were calculated as dpm/mg protein.
Each set of data was normalized by taking percentages
relative to control incubations that excluded drug
treatments. Data from two or three separate runs of the
experiments were then pooled for statistical analysis and
graphical representation as shown. Similarly, enzyme
activity data were normalized against each day and tis-
sue controls, and the data pooled for analysis. Statistical
analyses were by One-Way ANOVA followed with post-
hoc Tukey tests to compare all possible pairs of group
means or the Dunnett test to compare each treatment
mean to its respective control group as indicated in the
figure legends. Statistical comparisons were considered
significant at p < 0.05 or better.
Results
Effects of serotonin depletion on the effectiveness of
various antidepressant agents
Control and serotonin-depleted tissues from the rat hip-
pocampus or frontal cortex were tested for CDP-diacyl-
glycerol responses to various antidepressant agents. The
tissue slices were prelabeled with [3H]cytidine and then
incubated with maximally effective concentrations of the
antidepressant drugs fluoxetine (FLX, 100 μM), imipra-
mine (IMI, 300 μM), or maprotiline (MAP, 100 μM);
these dose selections were based on previously published
studies with brain slice preparations [2,3]. While similar
results were obtained in the hippocampus and frontal
cortex, the results for the frontal cortex are shown in
Fig. 1. Imipramine, fluoxetine, or maprotiline induced
significant accumulations of CDP-diacylglycerol in the
saline-pretreated control tissues as expected. Tissues
depleted of serotonin also gave significant responses to
the antidepressant agents, although the responses to
fluoxetine in the frontal cortex and to fluoxetine and
maprotiline in the hippocampus were significantly but
partially (21-32%) reduced in p-chlorophenylalanine
(PCPA)-pretreated tissues. The concentration and con-
ditions of PCPA treatment in these experiments are
known to result in practically complete depletion of ser-
otonin from the tissues [7-9].
Antidepressant drugs increase the synthesis of CDP-
diacylglycerol and phosphatidylinositides in PC12 cells
PC12 cells prelabeled with [3H]cytidine were incubated
with different concentrations of antidepressant drugs
ranging from 0.1 μM to 300 μM and the accumulation
of CDP-diacylglycerol assayed after 3 h. The results are
shown in Fig. 2. Imipramine (tricyclic antidepressant),
maprotiline (norepinephrine and serotonin reuptake
inhibitor), and paroxetine (selective serotonin reuptake
inhibitor) each significantly and concentration-depen-
dently increased the levels of CDP-diacylglycerol in the
PC12 cells [ANOVA, p < 0.0001]. Based on the posthoc
Dunnett tests, significant effects were obtained at con-
centrations of 30 μM and higher.
To test if antidepressant-induced increases in CDP-
diacylglycerol translated into enhanced synthesis of
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phosphatidylinositides in PC12 cells, another batch of
the cells was prelabeled with [3H]inositol and aliquots
tested with the drugs. Maprotiline and imipramine sig-
nificantly and dose-dependently increased phosphatidyli-
nositide levels in PC12 cells (Fig. 3). The effects of
imipramine were statistically significant at concentra-
tions of 1 μM and higher, while the effects of maproti-
line became significant at 3 μM and higher
concentrations. Ten micromolar and higher concentra-
tions of fluoxetine and paroxetine were also tested for
effects on phosphatidylinositides; while the 10 and 30
μM concentrations showed significant enhancement of
phosphatidylinositide synthesis, the 100 μM and higher
concentrations caused a reduction of labeling below
control levels, suggesting possible toxicity at the higher
concentrations (data not shown). Taken together, the
two neurolipid results (Figs. 2 and 3) suggest that anti-
depressants can increase CDP-diacylglycerol synthesis
which translates to increased phosphatidylinositide
synthesis in PC12 cells.
Figure 1 Effects of PCPA-induced serotonin depletion on
antidepressant stimulation of CDP-diacylglycerol synthesis in
brain tissue. Brain slices were prepared from the frontal cortex or
hippocampus tissues of saline-injected control rats or animals that
had been administered p-chlorophenylalanine (PCPA) to deplete
endogenous serotonin stores. The tissue slices were labeled with
[3H]cytidine and then incubated with predetermined concentrations
of the antidepressant drugs fluoxetine (FLX, 100 μM), imipramine
(IMI, 300 μM), or maprotiline (MAP, 100 μM). After 90 min,
accumulated [3H]CDP-diacylglycerol was measured. Data were
calculated as percentages relative to the respective basal
accumulations in the control or PCPA group. Each bar represents
the mean ± SEM (N = 6). PCPA treatment had no significant effect
on basal [3H]CDP-diacylglycerol accumulation in either tissue; such
basal effects being, respectively, 8194+806 v. 8555+1657 for control
versus PCPA in frontal cortex, and 8026+1295 v. 8139+1642 for
control versus PCPA in hippocampus. Each drug induced significant
accumulations of [3H]CDP-diacylglycerol in either the control or
PCPA tissues (ANOVA, p < 0.0001 for each drug). PCPA partially
reduced FLX and MAP effects but did not eliminate any of the drug
effects: ***p < 0.001, compared by posthoc Tukey tests.
Figure 2 Effects of antidepressant agents on [3H]CDP-
diacylglycerol synthesis in PC12 cells. PC12 cells were prelabeled
with [3H]cytidine for 30 min and cells in different culture wells
incubated with various concentrations of the antidepressant drugs
imipramine, paroxetine or maprotiline. [3H]CDP-diacylglycerol was
determined after 3 h. Data were calculated as percentages relative
to the control incubations that received no drug treatment. Each
bar represents the mean ± SEM (N = 3 experiments). The drug
treatments increased [3H]CDP-diacylglycerol significantly (ANOVA, p
< 0.0001 for each drug). Posthoc Dunnett tests showed statistically
significant increases in CDP-diacylglycerol at 30 and 100 μM. *p <
0.05; ***p < 0.001, compared to controls.
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Antidepressants increase CDP-diacylglycerol synthase
activity in mouse frontal cortex
The enzyme activity of CDP-diacylglycerol synthase (CDS)
was determined by measuring the rate of incorporation of
tritiated CTP into CDP-diacylglycerol, and the results are
shown in Fig. 4. Each of the antidepressants, imipramine,
paroxetine, and maprotiline, significantly increased CDS
activity (ANOVA, p < 0.001 for each drug). The posthoc
Dunnett tests showed that the effects of each drug attained
statistical significance at concentrations as low as 3 μM,
and then peaked right afterwards at 10 μM (imipramine)
or 30 μM (paroxetine and maprotiline). Thus, drug stimu-
lation of CDS activity may underlie the positive drug
effects on CDP-diacylglycerol synthesis.
Discussion
The classic action of antidepressants is to inhibit the reup-
take of monoamines which leads to increased synaptic
levels of the transmitters. The subsequent postsynaptic
actions of the monoamines on their cognate signaling sys-
tems may then lead on to produce the clinical antidepres-
sant effect [17-19]. However, such postsynaptic actions
have not been fully elucidated, although various tertiary
signaling effects ranging from alterations of ion channel
activity to modulation of protein kinases and gene tran-
scription have been proposed [17,20-22]. Taking clues
from a recent study showing that antidepressants concen-
tration-dependently increase the levels of CDP-diacylgly-
cerol and phosphatidylinositides in brain tissue
preparations [2], we have now addressed the question of
the extent to which this neurolipid effect may involve
actions of the monoamine transmitters. The data demon-
strate that various antidepressants increase phosphatidyli-
nositol and CDP-diacylglycerol synthesis probably through
stimulation of the enzymatic activity of CDS, the enzyme
that synthesizes CDP-diacylglycerol. While not all antide-
pressant agents depend on serotonin signaling for their
actions [9], a demonstration that the neurolipid effects of
selective serotonin reuptake inhibitors involves multiple
mechanisms should suffice as proof of the concept that
not all actions of antidepressants depend on monoamine
reuptake inhibition.
PCPA is often used to deplete tissues of serotonin
content either in vivo or in vitro [7-9]. Protocols used
here were similar to those used in numerous other
Figure 3 Effects of antidepressant agents on
phosphatidylinositide synthesis in PC12 cells. PC12 cells were
labeled with [3H]inositol and cells in different culture wells
incubated with various concentrations of selected antidepressant
drugs. After 3 h, accumulated [3H]phosphatidylinositides were
determined and the data calculated as percentages relative to
control. Each bar represents the mean ± SEM (N = 3 experiments).
Each drug treatment increased the levels of [3H]
phosphatidylinositides significantly and concentration-dependently
(ANOVA, P < 0.0001 for each drug). Posthoc Dunnett tests showed
statistically significant increases in phosphatidylinositides at 1-30 μM
for imipramine and at 3-30 μM for maprotiline. *p < 0.05; ** P <
0.01; ***p < 0.001; compared to controls.
Figure 4 Antidepressant drug effects on CDP-diacylglycerol
synthase activity in mouse cortex tissues. The enzymatic activity
of CDP-diacylglycerol synthase (CDS) was measured in mouse
cortical tissue preparations by determining the incorporation of
radiolabeled cytidine derived from 5- [3H]CTP into CDP-
diacylglycerol. Antidepressant agents were tested at concentrations
ranging from 1 μM to 100 μM. Data from each assay were
normalized against the control samples by calculating the
percentages shown. Each bar is the mean ± SEM (N = 3
experiments). One-Way ANOVA analyses for each drug showed
significant effects for imipramine (p < 0.001), maprotiline (p <
0.0001), and paroxetine (p < 0.01). Posthoc Dunnett tests showed
that imipramine and maprotiline elicited significant effects at 3-100
μM concentrations while with paroxetine significant effects were
evident at concentrations of 3-30 μM. *p < 0.05; ** P < 0.01; ***p <
0.001, compared to controls.
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studies some of which had the residual content of sero-
tonin assayed to assure the expected depletion. Thus,
even though we did not measure residual serotonin in
the present study, there is strong precedent to assume
that the agent worked as expected. Moreover, the signif-
icant reduction of the effect of fluoxetine (a selective
serotonin reuptake inhibitor) in the PCPA-treated tis-
sues supports the presumption that there was depletion
of the monoamine. Unlike the fluoxetine results, there
was no inhibition of imipramine (a serotonin/norepi-
nephrine reuptake inhibitor) in any tissue, or of mapro-
tiline (a norepinephrine reuptake inhibitor) in the
frontal cortex, thus indicating that the actions of these
agents on CDP-diacylglycerol or phosphatidylinositide
synthesis do not require serotonin. A desirable comple-
mentary experiment would be to test if other tissues
that are depleted of norepinephrine would show reduc-
tions in imipramine or maprotiline responses.
PC12 cells are widely used as a model of neuronal cell
metabolism [23,24]. The primary reason we chose PC12
cells was to use a model system that represents practi-
cally complete lack of endogenous monoamines, notably
serotonin and norepinephrine [6]. The marked and
dose-dependent stimulation of CDP-diacylglycerol and
phosphatidylinositide synthesis by imipramine as well as
maprotiline and paroxetine in PC12 cells implies that
monoamine neurotransmitters do not play a major role
in the nucleolipid effects of the drugs. Interestingly,
there was no significant effect of the drugs on inositol
phosphate accumulation in PC12 cells (data not shown).
The accumulation of inositol phosphates requires recep-
tor-coupled stimulation of phospholipase C. Hence,
while the antidepressants are able to enhance the pro-
duction of substrate for the phospholipase C reaction,
the drugs are apparently incapable by themselves to
induce the breakdown of these substrates into active
second messengers. This observation is in agreement
with our previous proposition of a tandem signaling
model for antidepressant-monoamine transmitter func-
tion. By this model, the antidepressants increase the
availability of phosphatidylinositide substrates and then
enhance the synaptic levels of the monoamines which
then act on their cognate postsynaptic receptors to con-
vert the phosphatidylinositide substrates into functional
second messengers.
It was noted that the antidepressant drugs significantly
enhanced phosphatidylinositide levels at concentrations
that were clearly lower than the concentrations neces-
sary to observe significant accumulations of CDP-diacyl-
glycerol. Given that CDP-diacylglycerol synthase activity
is considered to be rate-limiting, it is likely that any
CDP-diacylglycerol formed is quickly converted to phos-
phatidylinositide. As such, accumulation of CDP-diacyl-
glycerol may not become evident until the mechanism
for synthesizing phosphatidylinositides begins to saturate
at the higher drug concentrations. Additionally, phos-
phatidylinositol is able to accumulate because, as
explained above, there is no mechanism to stimulate the
activity of phospholipase C which is required to break
down the phospholipid. Based on the tandem signaling
model, one may predict that in the in vivo environment
the direct CDP-diacylglycerol effect and the indirect
monoamine reuptake effects of the antidepressant drugs
would work in concert to enhance both the generation
of substrate and the receptor-mediated release of intra-
cellular second messengers.
Following the foregoing results, it still remained to be
investigated how the antidepressants increase the levels
of the neurophospholipids in a direct manner that may
not be dependant on monoamine reuptake inhibition.
First, we considered if this action was related to the lipi-
dosis that has been associated with a number of amphi-
philic compounds, a group of chemical structures that
includes the tricyclics and several other antidepressants.
Amphiphiles are thought to induce lipidosis (nonspecifi-
cally increased lipid synthesis) through inhibition of
phospholipases that then progresses to the inhibition of
phospholipid degradation [25-27]. Other observations
suggest that increased cellular phosphatidylinositide
levels have an inductive effect that increases non-phos-
phatidylinositide-derived glycerolipid synthesis [28]. If
so, then a primary action of antidepressants on CDP-
diacylglycerol synthesis could lead to increased phospha-
tidylinositide synthesis, which may then enhance the
synthesis of other non-phosphatidylinositide-containing
lipids.
It is still unclear if imipramine or any of the other
agents interact directly with the phospholipids to pre-
vent their degradation or inhibit phospholipases [29]. If
the tested antidepressant drugs induced phosphatidyli-
nositide accumulation solely through inhibition of phos-
phatidylinositide metabolism, then there should not
have been an increase in CDP-diacylglycerol, which is
upstream of phosphatidylinositol and whose levels are
tightly controlled by the rate-limiting activity of CDS.
Moreover, in brain slices, co-incubation of antidepres-
sant with direct agonists of 5HT2 receptors resulted in
enhanced accumulations of inositol phosphates over and
above the effects due to agonist alone, implying that
phosholipase C may not have been inhibited (or at least
that enzyme stimulation by a coupled receptor was not
prevented) [3]. Taken together, it appears that enhanced
synthesis rather than inhibited degradation may explain
the observed drug-induced increases in the levels of sig-
naling phospholipids.
Based on the observation that chemically diverse anti-
depressants increased the synthesis of the phospholipids,
we hypothesized that the drugs enhance the activity of
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the phospholipid synthesizing enzymes. This prompted
the need to investigate the effects of the drugs on CDP-
diacylglycerol synthase activity. CDS is reported to have
high activity in the brain based on distribution analysis
in rodent tissues [30]. Further, the cortex was selected
for testing seeing that cognitive abnormalities such as
hopelessness, memory impairments, suicidality and guilt
in many depressed patients are thought to be associated
with, or mediated through, the frontal cortex region of
the brain. In general, the cortex might also regulate the
emotional behavior abnormalities [31]. Although the
tested drugs were chemically different, the drugs shared
a common enhancing effect on CDS activity in the cor-
tex. CDS activity was increased at drug concentrations
of 3 μM and above, which is consistent with our pre-
vious report where the antidepressants increased CDP-
diacylglycerol accumulation in rat cortex slices at con-
centrations of 1-3 μM and above [2]. That all three
tested agents enhanced the enzymatic activity of CDS
provides a plausible explanation for the enhanced synth-
esis of CDP-diacylglycerol and phosphatidylinositides.
The detailed mechanism by which the drugs induce
CDS activity, however, remains to be explored.
One concern about these observations was the poten-
tial toxicity of the antidepressants given that the effec-
tive concentrations were in the micromolar range (3-300
μM). A previous report showed that antidepressants
such as fluoxetine (selective serotonin reuptake inhibi-
tor) and amitriptyline (non selective reuptake inhibitor)
did not adversely affect cell survival of PC12 cells up to
100 μM for 24 or 48 h incubation periods [32]. These
drugs even appeared to exert a neuroprotective effect on
PC12 cells against neurotoxic insults like 200 μM hydro-
gen peroxide by upregulating superoxide dismutase
activity [32]. In another recent study examining the
anti-inflammatory properties of tricyclic antidepressants,
concentrations of 10 or 20 μM imipramine did not
reduce cell viability in the MTT assay in microglia and
astrocytes incubated in vitro for up to 24 h [33]. In
humans undergoing therapy with imipramine, drug
levels reach on average 0.54 μM in the plasma [34,35].
Imipramine and similar drugs, however, accumulate in
brain tissue 32-fold higher than the level in the plasma
or the serum [36]. If so, then the final concentrations to
which the brain is exposed are actually comparable to
the concentrations of imipramine that showed signifi-
cant effects in each of the present measures.
Conclusions
In conclusion, the results of this study raise the possibi-
lity that the neurolipid effects of antidepressant agents,
particularly on CDP-diacylglycerol and phosphatidylino-
sitide synthesis, may be independent of monoamine
transmitter action. Given that resting cellular levels of
CDP-diacylglycerol are thought to be rather low, and
that CDS activity is the rate - limiting step in CDP-dia-
cylglycerol synthesis, enhancing the activity of CDS
appears to be a logical or plausible explanation for the
effect of antidepressants on CDP-diacylglycerol and
phosphatidylinositide synthesis.
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